Stockreport

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer [Yahoo! Finance]

Merus N.V. - Common Shares  (MRUS) 
Last merus n.v. - common shares earnings: 8/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/mrus
PDF clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) and Partner Therapeutics, Inc. (PTx), a private, [Read more]